-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2025-521590-13-00
5
Moderately to Severely Active Crohn’s Disease
-
2025-522093-36-00
10
2026-05-20
Cancer cachexia
-
2024-519870-38-00
5
2026-05-11
Atherosclerotic cardiovascular disease (ASCVD)
-
2025-521936-12-00
5
2026-04-24
Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline re
-
2024-517968-36-00
5
2025-07-08
non-small cell lung cancer
-
2024-513054-30-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2023-504307-88-00
5
2024-02-20
Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
-
2025-523658-15-00
5
2026-04-10
Obesity
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2025-520566-22-00
5
2025-11-10
Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
-
2024-518914-18-00
4
2025-08-27
Moderate to Severely Active Ulcerative Colitis & Moderate to Severely
-
2024-519525-38-00
5
2025-08-22
Heart failure
-
2023-506704-14-00
4
2024-09-04
Moderately to Severely Active Crohn's Disease
-
2023-503224-66-00
5
2023-10-31
Atrial Fibrillation
-
2023-503661-28-00
5
2023-10-26
Hidradenitis Suppurativa
-
2025-520488-42-00
4
2025-09-17
Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-513015-27-00
5
2025-01-09
Moderately to Severely Active Ulcerative Colitis (UC)
-
2024-510730-40-00
5
2024-12-12
Hidradenitis Suppurativa
-
2023-509301-80-00
5
2024-11-04
Severe hypertriglyceridemia (SHTG)
-
2023-509302-30-00
5
2024-11-04
Hypertriglyceridemia
-
2023-506769-67-00
4
2024-09-04
Moderate to Severely Active Ulcerative Colitis
-
2023-508630-34-00
5
2024-05-28
Overweight